For functional & integrative medicine · 381 biomarker genes

When the labs read normal but the patient isn’t.

Bulk panels average signals across billions of cells and call it ‘normal.’ CellWise reads 381 biomarker genes across immune cell populations, shows you which cells are dysregulated and why, and names the exact follow-up labs to order next.

See what it costs
✓ Founding pilot rate: $1,800 a patient ✓ Root-cause resolution ✓ No repeat sequencing to keep using it
CellWise · Autoimmune Stratification
IFN signature
Elevated
BAFF elevation
Elevated
Immunological axis · innate ↔ adaptive
Autoinflammatory · innateAutoimmune · adaptive
Reproductive · CXCL10
Elevated
Adaptive signal · mean z
+2.22
Next step · comprehensive autoimmune panel
ANA (titer + pattern) · dsDNA · Anti-Smith · Anti-RNP
Grounded inreal population datapeer-reviewed researchlegacy single-cell technology
Founding Practitioner Pilot · fifty places

Up to five of your own patients at $2,095 $1,800 each, for Core Plus.

14% below standard Invoiced only for the ones you send.All in: kit, shipping and the blood draw.A sample that fails lab QC is not invoiced.Decide at the end of a 30-day review.
Per patient
$1,800

Core Plus, 14% below the $2,095 standard rate.

How many
One to five

Your own patients. Invoiced only for the ones you send.

Billing
On delivery, net 30

All in: collection kit, shipping and the phlebotomy draw. A failed QC sample is not invoiced.

Your decision
30-day review

Full module access from your last report, then decide whether to carry on.

Fifty founding places.Full pricing and terms
What it actually solves

Where root-cause medicine keeps hitting a wall.

The gaps between a symptomatic patient and an actionable answer.

The 'normal labs' dead end

Bulk panels average signals across billions of cells and call it normal. CellWise reads gene expression across 381 biomarker genes across immune cell populations to show which cells are dysregulated, and why.

Resolution where standard panels go quiet

Trial-and-error protocols

Without objective molecular data, treatment becomes iteration. The immuno-metabolic phenotype and missing-biomarker interrogation name the exact workup the pattern warrants before you order a conventional test.

Front-load the mechanism, skip the guessing

Months to a coherent diagnosis

Complex autoimmune and inflammatory cases wander between referrals. CellWise converges scattered signals into a single narrative that points straight at the right panel.

Faster to the answer, and the referral
Rotates every few seconds. Hover to pause, click a headline to hold it.
Root cause, read as pathways switching on and off.

Inflammation and detox defence are programmes with a source: a cell type, a pathway, a direction. Real data from 26 reference donors with no known diagnosis: each column is one person, each row one gene in one cell type, coloured against people of the same sex.

Inflammasome and IL-1 on in 7 of 26 donors 26 reference donors, no known diagnosis. One column per person. Inflammasome and IL-1 ↑ switched on when the state is present IL1B · CD14 monocytes CXCL8 · CD14 monocytes NLRP3 · CD14 monocytes CASP1 · CD14 monocytes NRF2 detox defence ↑ switched on when the state is present NFE2L2 · CD14 monocytes GCLM · NK cells HMOX1 · CD14 monocytes
Lower than reference Higher than reference not read Robust z-score of each gene in its cell type against same-sex reference donors (colour capped at ±5). Hover a square for the value.
  • Inflammasome genes on in monocytes: where the inflammation comes from, by cell, not just that a marker is high.
  • NRF2 detox defence: whether the antioxidant response is mounting or standing down in that same person.
  • Confirm with the labs each pathway names. A switched-on programme is the reason to order hs-CRP or the follow-up test, not a diagnosis.
Everything in the portal

Seven modules, one clinical workspace.

Health Analysis ReportIllustrative preview
SemaglutideGLP-1 receptor agonist · mapped with tirzepatide
Strong match
  1. Cell stateInnate inflammation on, in CD14 monocytes
  2. Genes4 move with the state, 1 against
  3. PathwayNF-κB and IL-1β
  4. MechanismLowered IL-1β and TNF in mononuclear cells in a randomised trial; pooled trials lower CRP. Human data
  5. Check firstA recent infection or vaccine, or hard exercise before the draw
In line with the state
IL1B ↑CXCL8 ↑NLRP3 ↑TNF ↑
Moving against it
CCL2 ↓

Read in this patient's CD14 monocytes against people of the same sex in the reference set.

Mechanism: human dataResponse: CellWise prediction, not yet validated
Module 01

Health Analysis Report

The clinical home base: risk-rated health domains, immuno-metabolic phenotyping, and mechanism-based peptide pairing, each call traced from cell state to genes, pathway and mechanism.

Clinicians see
Each peptide call explained: the cell state, the genes moving with it and against it, the pathway, the evidence tier and what to check first.
Licensees get
Report templates in your brand, under co-brand or white-label.
Biomarker AnalyticsIllustrative preview
S100A12
IL1B
ISG15
CCR7
TCF7
PRF1
HSPA5
same-sex reference rangethis patient
Module 02

Biomarker Analytics

The quantitative, visual view of the patient's raw biomarker data, shown as a population-vs-patient overview.

Clinicians see
Every panel gene placed against the same-sex reference population, the outliers first.
Licensees get
The same views themed to your interface, or piped through the API.
Data ExplorerIllustrative preview
IL1B
Cell populationDirectionSignal
CD14 monocytes↑
CD16 monocytes↑
pDCs↑
CD4 T cells·
Module 03

Data Explorer

A filterable, gene-level interface over the patient's complete dataset, exposing the top cell populations carrying each signal.

Clinicians see
Filter by gene, cell type or direction and see which populations carry each signal.
Licensees get
Gene-level data your scientific team can query, not just a PDF.
Clinical Scenario SimulatorIllustrative preview
HypothesisWhat if this patient starts a GLP-1 receptor agonist?
Re-running against this patient's data
Inflammasome tone
Insulin signalling
Interferon response
Module 04

Clinical Scenario Simulator

Test a clinical hypothesis against the patient's own molecular data and re-run it in seconds.

Clinicians see
Pose a clinical hypothesis against the patient's own data and re-run it in seconds.
Licensees get
A consult tool that keeps clinicians working inside your platform.
Outcomes & MonitoringIllustrative preview
BaselineLoadingMaintenance
Peptide-specific labWearable trend (HRV)
Module 05

Outcomes & Monitoring

Assay-independent surveillance across dosing phases, peptide-specific labs, and wearable trends, with no repeat sequence required.

Clinicians see
Peptide-specific labs and wearable trends tracked across dosing phases, between screens.
Licensees get
A monitoring loop that brings patients back to your menu between draws.
Cellular Aging ProfileIllustrative preview
Immune agewhich compartments are aging fastest, and which hallmarks drive it
Genomic instabilityTelomere attritionEpigenetic alterationProteostasisAutophagyNutrient sensingMitochondriaSenescenceStem-cell exhaustionCommunicationInflammationDysbiosis
Module 06

Cellular Aging Profile

Immune age, senescence, and the 12 hallmarks from one PBMC sample, for cell-resolved biological aging.

Clinicians see
Immune age, senescence and the 12 hallmarks of aging from one PBMC sample.
Licensees get
A preventative-health line item you can list under your own name.
Longitudinal ScreeningIllustrative preview
IL1B · CD14 mono
↓
ISG15 · CD16 mono
·
CCR7 · CD4 T
↑
DDIT3 · NK
↓
Screen 1Screen 2
Module 07

Longitudinal Screening

Re-assay a patient and see the gene-expression deltas across key biomarkers, so you see what has shifted since the last screen.

Clinicians see
Re-assay and see exactly which genes moved, in which cells, since the last screen.
Licensees get
Re-assay built into the product, so the second test is part of the plan.
Hover or tap a module to stop on it. Previews are illustrative.
What the beta measured

The signal under a ‘normal’ result.

Three reviewers read the same donor in isolation, and each surfaced the same contraindication and the same targeted labs a standard panel would never generate.

381
Biomarker genes across immune cell populations, catching cell-specific abnormalities bulk panels average away.
Cell type
Every reported signal resolved to the cell populations driving it, instead of averaged across billions of cells.
8–12
Additional targeted lab orders surfaced that a standard annual panel would never have generated.
$3–5k
Downstream testing avoided per complex patient by front-loading the mechanistic picture instead of iterating toward it.
2–3 hrs
Of literature synthesis replaced, connecting expression to hypothesis to intervention, done for you.
Δ
Longitudinal re-assay shows whether the root-cause intervention actually shifted the signature.
From the review room

Same donor. Same hidden signature. No cross-talk.

“

The 'Very High' autoimmune risk with the CXCL10/BAFF/IFN signature is clinically coherent and would prompt me to order an ANA panel, dsDNA, and complement levels before proceeding with any immunostimulatory peptides. The report even lists the specific missing biomarkers (Anti-SSA/Ro, Anti-SSB/La, C3/C4), which is genuinely useful chart prep.

Rheumatology MD
Beta review
“

This is the resolution root-cause medicine has always needed. It tells me which cells are inflamed, not just that inflammation exists.

Functional Medicine MD
Beta review
“

It named three follow-up labs I’d have reached only after two more visits of trial and error.

Integrative Medicine DO
Beta review
◆ Illustrative, not testimonial. These show the kind of read the report supports, drafted from clinician personas during beta design rather than quoted from named practitioners. Reviews from the founding pilot will replace them.

Investigate up to five patients, at the founding rate.

Join the founding pilot: up to five of your own patients at $1,800 each, 14% below the standard rate, invoiced only for the ones you send. Founding rates lock for twelve months if you go forward, and every pilot practice is a design partner with a say on what gets built. Open to a limited cohort of functional and integrative practices.